- Home
- FOA vs TVRD Comparison
FOA vs TVRD Comparison
Compare FOA & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- TVRD
- Stock Information
- Founded
- FOA 2013
- TVRD 2017
- Country
- FOA United States
- TVRD United States
- Employees
- FOA N/A
- TVRD N/A
- Industry
- FOA Finance Companies
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- TVRD Health Care
- Exchange
- FOA Nasdaq
- TVRD Nasdaq
- Market Cap
- FOA 248.8M
- TVRD 246.5M
- IPO Year
- FOA N/A
- TVRD N/A
- Fundamental
- Price
- FOA $22.93
- TVRD $27.13
- Analyst Decision
- FOA Buy
- TVRD Strong Buy
- Analyst Count
- FOA 2
- TVRD 5
- Target Price
- FOA $27.50
- TVRD $59.20
- AVG Volume (30 Days)
- FOA 104.1K
- TVRD 93.1K
- Earning Date
- FOA 08-05-2025
- TVRD 08-21-2025
- Dividend Yield
- FOA N/A
- TVRD N/A
- EPS Growth
- FOA N/A
- TVRD N/A
- EPS
- FOA 3.94
- TVRD N/A
- Revenue
- FOA $429,184,000.00
- TVRD N/A
- Revenue This Year
- FOA $21.89
- TVRD N/A
- Revenue Next Year
- FOA $8.91
- TVRD N/A
- P/E Ratio
- FOA $5.86
- TVRD N/A
- Revenue Growth
- FOA 155.35
- TVRD N/A
- 52 Week Low
- FOA $6.13
- TVRD $8.13
- 52 Week High
- FOA $32.40
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- FOA 54.57
- TVRD N/A
- Support Level
- FOA $22.75
- TVRD N/A
- Resistance Level
- FOA $24.17
- TVRD N/A
- Average True Range (ATR)
- FOA 0.74
- TVRD 0.00
- MACD
- FOA -0.03
- TVRD 0.00
- Stochastic Oscillator
- FOA 61.94
- TVRD 0.00
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.